TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
At the American Academy of Dermatology meeting in Denver, dermatologist Brian Kim discussed several approaches under study or in use for chronic urticaria, including BTK inhibition, c-KIT targeting and IL-4 receptor blockade. Remibrutinib is approved for chronic spontaneous urticaria, while its phase III results in three forms of chronic inducible urticaria and other emerging strategies need further context on regulatory status and availability.
Dermatologist Brian Kim outlined several treatment approaches for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) in a MedPage Today video recorded after the American Academy of Dermatology meeting in Denver. The approaches include an approved BTK inhibitor for CSU, reported phase III results in three CIndU types, and continued development of therapies targeting IL-4 receptors and mast cells.
Kim, a professor of dermatology and vice chair of research at the Icahn School of Medicine at Mount Sinai, identified remibrutinib (Rhapsido) as a prominent topic at the meeting. He described it as a recently approved Bruton’s tyrosine kinase (BTK) inhibitor for CSU. He also said phase III data had been reported for remibrutinib in three forms of CIndU: dermatographism, cold urticaria and cholinergic urticaria. The supplied report does not provide trial results, participant numbers or details of regulatory decisions for those CIndU uses.
Kim also discussed dupilumab (Dupixent), which blocks the IL-4 receptor and is a treatment topic in CSU. Another focus was barzolvolimab, a c-KIT inhibitor. Kim said the drug may inhibit mast cells and may also deplete them. His description of that mechanism was presented as a probability, not as a confirmed clinical outcome in the source material.
Kim disclosed a conflict of interest: he co-founded Alys Pharma, which he said is developing a bispecific c-KIT inhibitor intended to block c-KIT specifically on mast cells. He characterized it as a strategy to build on approaches such as barzolvolimab. The video report provides no clinical results or development timeline for Alys Pharma’s candidate.
More Targets, Different Treatment Questions
The range of mechanisms discussed points to more than one therapeutic route being explored for chronic urticaria. That matters to patients and clinicians because CSU and CIndU are distinct conditions, and an approach or result in one form of urticaria does not by itself establish benefit in another. The reported remibrutinib data across dermatographism, cold and cholinergic urticaria may be relevant to future options, but the source does not give enough detail to judge the size or durability of any effect.
The c-KIT strategies raise a separate question: whether targeting mast cells, or selectively targeting c-KIT on those cells, can provide useful treatment. At this stage, the report records a specialist’s account of research directions, not comparative evidence showing that one treatment works better than another. Patients should not interpret discussion of emerging candidates as confirmation that those medicines are available or appropriate for them.
chronic urticaria treatment options
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The AAD Meeting’s CSU Session
The AAD session described in the report was only the second session on CSU at the meeting series, following an earlier session at a prior AAD meeting. The discussion in Denver covered several biological targets: IL-4 receptor blockade, BTK inhibition, and c-KIT and mast-cell approaches. This is the immediate context for Kim’s comments about a broader treatment landscape.
The source is a short video and transcript published by MedPage Today on October 8, 2026, and says the interview was recorded after the meeting in April. It summarizes Kim’s remarks rather than presenting a full trial report or formal meeting proceedings. Its account supports the existence of active clinical and drug-development discussion, but does not establish the efficacy, safety or approval status of every approach mentioned.
“They’ve reported really great phase III data in chronic inducible urticaria across three different domains.”
— Brian Kim, MD
As an affiliate, we earn on qualifying purchases.
Evidence and Approval Details Remain Limited
The meeting-video source does not report trial sizes, effect measurements, safety findings or follow-up periods for the phase III CIndU results Kim referenced. It also does not state whether remibrutinib has been approved for any CIndU indication. The report identifies it as approved for CSU, but gives no further prescribing or regulatory details.
The status of barzolvolimab and Alys Pharma’s bispecific candidate is also not fully described. No clinical outcome data, approval decisions or expected timelines are provided for either c-KIT approach. Kim’s disclosure is relevant when weighing his comments on the company’s candidate; the source does not independently evaluate its potential or compare it with other drugs.
As an affiliate, we earn on qualifying purchases.
Watch for Trial and Regulatory Updates
The next useful milestones will be fuller publication or presentation of the remibrutinib phase III CIndU results, including the methods, measured outcomes and safety data, as well as any regulatory updates on use beyond CSU. For c-KIT-targeting therapies, readers will need clinical-trial results and development updates to understand whether the proposed mast-cell effects translate into patient benefit.
The source does not announce a specific upcoming study release, regulatory decision or timetable. Until those details are available, the developments described at the AAD meeting are best understood as a mix of an approved CSU treatment and ongoing or reported research across other forms of urticaria.
As an affiliate, we earn on qualifying purchases.
Key Questions
What treatment development was discussed at the AAD meeting?
Brian Kim discussed remibrutinib, an approved BTK inhibitor for CSU, reported phase III data in three CIndU types, and research approaches involving IL-4 receptor blockade and c-KIT targeting.
Is remibrutinib approved for chronic inducible urticaria?
The source describes remibrutinib as approved for chronic spontaneous urticaria and says phase III data were reported in dermatographism, cold urticaria and cholinergic urticaria. It does not say that the drug is approved for those CIndU conditions.
What is barzolvolimab?
Kim described barzolvolimab as a c-KIT inhibitor that may inhibit mast cells and may also deplete them. The report does not include clinical results or its regulatory status.
What is known about the bispecific c-KIT approach?
Kim said Alys Pharma, a company he co-founded, is developing a bispecific strategy intended to block c-KIT on mast cells. The source provides no trial results or development timeline for that candidate.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
